6505--Zonisamide Capsules
ID: 36E79726R0005Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/b4814d124eb2431daccfe412f47152e0/view
Timeline
    Description

    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.

    Point(s) of Contact
    Christopher CarthronContract Specialist
    Christopher.Carthron@va.gov
    Files
    Title
    Posted
    36E79726R0005_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center intends to issue RFP 36E79726R0005 for an unrestricted procurement of Zonisamide Capsules. This contract will supply the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The VA plans to award a single contract for one year, with four optional one-year extensions, to an offeror who can provide an uninterrupted supply. The solicitation, expected around December 15, 2025, with a tentative closing date of December 30, 2025, will be issued electronically in accordance with FAR Part 12. Offerors must provide the exact drug name and a unique NDC number. The estimated annual requirements include 41,351 bottles of 100mg, 4,539 bottles of 25mg, and 5,326 bottles of 50mg Zonisamide Capsules. All interested parties should monitor sam.gov for updates, and inquiries can be directed to Chris Carthron at Christopher.Carthron@va.gov.
    36E79726R0005.docx
    This government solicitation, 36E79726R0005, outlines a Firm Fixed Price, Indefinite-Delivery Requirements contract for pharmaceutical products, specifically Zonisamide Capsules (25mg, 50mg, and 100mg). The contract will establish national prices for these drugs, distributed through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs to various government healthcare facilities. Key requirements for offerors include providing prices for a base year and four option years, submitting a 0.5% Cost Recovery Fee, and adhering to strict packaging, barcoding (including DSCSA), and National Drug Code (NDC) standards. Offerors must also have FDA-approved manufacturing facilities with acceptable cGMP status, provide a Letter of Commitment if not the manufacturer, and maintain current SAM registration. The contract emphasizes compliance, outlining procedures for backorders, drug recalls, and the handling of covered drugs under 38 U.S.C. § 8126. Payments will be made by PPVs to the contractor, not directly by the government.
    Lifecycle
    Title
    Type
    6505--Zonisamide Capsules
    Currently viewing
    Solicitation
    6505--Zonisamide Capsules
    Presolicitation
    Similar Opportunities
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--770_Pharmaceuticals_VA CMOP National Office_36C77026Q0060
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of various dosages of Duloxetine HCl capsules, intended for delivery to multiple Consolidated Mail Outpatient Pharmacy (CMOP) locations across the United States. This presolicitation notice (36C77026Q0060) outlines a requirement for monthly deliveries over a three-month period, with specific quantities and packaging details for each item, emphasizing compliance with the Drug Supply Chain Security Act (DSCSA) and adherence to strict delivery and packaging standards. Interested vendors must submit their quotes, including a signed SF1449, a price schedule in Excel format, and a state wholesale distributor license, by January 2, 2026, with an estimated award date of January 23, 2026. For further inquiries, vendors can contact Contract Specialist Michael W. McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    6505--766-26-1-400-0207 -Charleston CMOP 2 Pharmaceuticals -(VA-26-00025368)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking to procure two specific pharmaceuticals, JASMIEL (J0040) 28-DAY TABLET and DROSPIRENONE 4MG (D1217), for the Consolidated Mail Outpatient Pharmacy (CMOP) in Ladson (Charleston). This procurement is critical as the products have been prescribed by VA physicians, and no substitutions are permitted due to the absence of alternative suppliers in the market. Vendors are required to submit a signed SF1449, a completed pricing schedule, a valid State Wholesale Distributor License, and a Buy American Act Certificate by January 5, 2026, at 3:00 PM CT, with deliveries staggered over a six-month period starting ten days after order receipt. Interested parties should direct their quotes to Kelley Cunningham at kelley.cunningham@va.gov.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    Lenalidomide/Revlimid - Brand Name or Equal
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to supply Lenalidomide/Revlimid medication, either brand name or equal, for the Edward Hines Jr. VA Hospital Pharmacy Service in Hines, Illinois. This procurement includes the delivery of various dosages of Lenalidomide capsules for a contract period from January 5, 2026, to January 4, 2027, and requires that the successful offeror be a pharmacy certified with the Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program. The medication is critical for treating certain conditions, and the procurement process will be based on the lowest price technically acceptable offers, with payment processing handled electronically through the Tungsten Network. Interested parties must submit their quotes via email to the primary contact, Arneil Genus, at arneil.genus@va.gov by the deadline of December 26, 2025, at 3 PM CST.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.